Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteIn July 2024, Seattle biotech startup Bonum Therapeutics planned to move into larger Eastlake offices and said it hoped to roughly double its 31-person team over the next few years. The expansion was meant to support development of early-stage immunotherapies designed to activate more selectively—not evidence that a cancer drug had reached patients or proven safer.
What Bonum planned in Seattle
Bonum expected to move in August 2024 from offices at the Access to Advanced Health Institute to the 11th floor of Alexandria Real Estate’s life-science tower at 1150 Eastlake Avenue East. CEO John Mulligan told GeekWire on July 18, 2024 that the company hoped to double its 31-person workforce within the next few years. That was a hiring ambition, not a reported outcome; the available company updates do not establish that the target was met.
The move placed Bonum in Seattle’s Eastlake and South Lake Union life-sciences corridor, near institutions including Fred Hutchinson Cancer Research Center and the Allen Institute. Mulligan said the company had identified the vacancy during the biotech downturn in 2022, when real-estate conditions were more favorable to tenants. More space could accommodate research and operational staff, but a larger footprint is an infrastructure decision—not proof of scientific progress.
Bonum’s connection to Good Therapeutics
Bonum grew out of Good Therapeutics, a Seattle biotech founded by Mulligan in 2016 to develop cancer drugs intended to act more selectively. Mulligan spun Bonum out before Roche acquired Good Therapeutics in 2022. Roche’s $250 million transaction included exclusive rights to Good’s leading preclinical program; it was an acquisition of Good Therapeutics, not Bonum.
#1 Best Overall
- 25 grams
- Assay >99%
- Net weight: 100 grams
After the transaction, Good Therapeutics’ team, equipment, and data moved to Bonum, which retained rights to other projects and the platform blueprint. Roche’s interest in Good’s lead program signals commercial interest in that predecessor’s work, but it does not validate Bonum’s separate retained candidates.
How the company was financed
The Washington State Life Science Investment Report for November 2022 lists a $93 million Series A for Bonum dated November 15, 2022, in Seattle. Listed investors included RiverVest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3×5 Partners, Codon Capital, and Vivo Capital. The report says its data came from S&P Global Market Intelligence and public disclosures and were not independently verified by Life Science Washington. The financing could support staffing and development, but the listed amount alone does not establish runway, spending, or whether a candidate will succeed. See the report.
Rank #2
- Feel Safe for the Quality of your DCA: Each batch of DCA-LAB Sodium Dichloroacetate is analysed for purity and quality in a Certified Third-Party Laboratory. Certificate of Analysis included in each bottle!
- Third-Party Tested! Premium Grade DCA from DCA Lab >99.9% Pure. Feel Assured: Every bottle of our Sodium Dichloroacetate includes a Certificate of Analysis!
- No Fillers: There are no fillers in DCA Lab products. The only ingredient in DCA Labs products is Sodium Dichloroacetate.
- Caring Customer Service: We will go the extra mile for our customers. Feel trust knowing that we will do everything to make things right for You in a courteous and prompt manner.
How Bonum’s conditionally active approach is supposed to work
The problem with cytokines
Cytokines are proteins that signal and regulate immune activity. Interleukin-2, or IL-2, can stimulate immune responses against cancer and has been used clinically for decades, but systemic exposure can cause serious effects, including vascular leak. The development challenge is to preserve useful immune stimulation while limiting activity in healthy tissues. Mulligan characterized IL-2’s toxicity in the GeekWire report; that description should not be treated as a quantified outcome for every patient or treatment.
The sensor concept
Bonum’s approach combines an immune-stimulating protein such as IL-2 with an antibody-based sensor. The sensor is intended to recognize a selected target and help make the cytokine active preferentially near cells bearing that target, rather than broadly throughout the body. Good Therapeutics had explored an IL-2 design paired with an antibody targeting PD-1. The Bonum program described in 2024 paired IL-2 with a sensor antibody targeting LAG3.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchThe intended advantage is localized activity; the central uncertainty is whether the engineered combination can activate reliably at the desired site without unwanted activity elsewhere. Less systemic exposure might also mean less immune stimulation where it is needed. Target expression can vary among tumors and patients, and engineered protein combinations must also be produced consistently and at scale. Bonum was evaluating candidates for activity, safety, and manufacturability, but the available reporting did not provide comparative toxicity data, a measured therapeutic window, or human results.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What was known about the cancer program
The IL-2/LAG3 effort was described as preclinical in the July 2024 report. It did not establish a formal candidate name, a specific tumor indication, an investigational new drug filing, human dosing, clinical efficacy, or FDA approval. A preclinical rationale is a starting point for development, not evidence that the approach works in people.
Bonum was also exploring potential partnerships beyond cancer immunotherapy, including possible applications in metabolic disease, pain, and autoimmune disease. Those were platform possibilities and business-development interests, not established clinical programs in the reporting.
What later company updates do—and do not—show
Bonum’s news archive lists an August 13, 2024 announcement about a U.S. Patent and Trademark Office patent related to its conditionally active biologics technology. The archive describes protection for a dual-binding antibody platform and gives examples including LRRC15–IFNα, PD-L1–IFNα, and PD-1–IL-2. A patent supports intellectual-property protection; by itself, it does not demonstrate efficacy, safety, regulatory progress, or commercial success.
The archive also lists a December 3, 2024 board appointment for Samuel C. Blackman, MD, PhD, along with media and podcast items in 2025 and 2026. Those entries show company activity, but they do not verify that the 2024 hiring goal was achieved or establish clinical advancement, new financing, revenue, or FDA status.
Quick Recap
What to watch when assessing Bonum’s progress
- A formal candidate name, intended cancer type, and clearly described development milestone for the LAG3/IL-2 program.
- Disclosure of preclinical results, including evidence about targeting, safety, and activity—not simply a platform description or patent.
- An investigational new drug filing, trial registration, or other verifiable step toward human testing.
- Evidence of actual hiring, facility use, financing, or licensing, distinct from plans and archive listings.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
